Adenocarcinoma, Clear Cell

"Adenocarcinoma, Clear Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)

Descriptor ID	D018262
MeSH Number(s)	C04.557.470.200.025.045
Concept/Terms	Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinomas, Clear Cell Clear Cell Adenocarcinoma Clear Cell Adenocarcinomas

Below are MeSH descriptors whose meaning is more general than "Adenocarcinoma, Clear Cell".

Diseases [C]
Neoplasms [C04]
Neoplasms by Histologic Type [C04.557]
Neoplasms, Glandular and Epithelial [C04.557.470]
Carcinoma [C04.557.470.200]
Adenocarcinoma [C04.557.470.200.025]
Adenocarcinoma, Clear Cell [C04.557.470.200.025.045]

Below are MeSH descriptors whose meaning is more specific than "Adenocarcinoma, Clear Cell".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Adenocarcinoma, Clear Cell" by people in this website by year, and whether "Adenocarcinoma, Clear Cell" was a major or minor topic of these publications.

Bar chart showing 12 publications over 6 distinct years, with a maximum of 5 publications in 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1994	0	1	1
2013	0	1	1
2015	1	0	1
2016	5	0	5
2017	3	0	3
2018	1	0	1

Below are the most recent publications written about "Adenocarcinoma, Clear Cell" by people in Profiles.

Chan JK, Brady W, Monk BJ, Brown J, Shahin MS, Rose PG, Kim JH, Secord AA, Walker JL, Gershenson DM. A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecol Oncol. 2018 08; 150(2):247-252.

View in: PubMed
Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ, Tewari K, Argenta PA, Mannel RS, Secord AA, Stephan JM, Mutch DG, Stehman FB, Muggia FM, Rose PG, Armstrong DK, Bookman MA, Burger RA, Farley JH. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol. 2017 11; 147(2):243-249.

View in: PubMed
Crim A, Rowland M, Ruskin R, Dvorak J, Greenwade M, Walter A, Gillen J, Ding K, Moore K, Gunderson C. Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women. Gynecol Oncol. 2017 08; 146(2):268-272.

View in: PubMed
Brasky TM, Felix AS, Cohn DE, McMeekin DS, Mutch DG, Creasman WT, Thaker PH, Walker JL, Moore RG, Lele SB, Guntupalli SR, Downs LS, Nagel CI, Boggess JF, Pearl ML, Ioffe OB, Park KJ, Ali S, Brinton LA. Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. J Natl Cancer Inst. 2017 03 01; 109(3):1-10.

View in: PubMed
Prendergast EN, Holzapfel M, Mueller JJ, Leitao MM, Gunderson CC, Moore KN, Erickson BK, Leath CA, Diaz Moore ES, Cohen JG, Walsh CS. Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort. Gynecol Oncol. 2017 Feb; 144(2):274-278.

View in: PubMed
Fader AN, Java J, Tenney M, Ricci S, Gunderson CC, Temkin SM, Spirtos N, Kushnir CL, Pearl ML, Zivanovic O, Tewari KS, O'Malley D, Hartenbach EM, Hamilton CA, Gould NS, Mannel RS, Rodgers W, Walker JL. Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. Gynecol Oncol. 2016 Dec; 143(3):460-465.

View in: PubMed
Garcia-Soto AE, Java JJ, Nieves Neira W, Pearson JM, Cohn DE, Lele SB, Tewari KS, Walker JL, Alvarez Secord A, Armstrong DK, Copeland LJ. Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. Gynecol Oncol. 2016 Dec; 143(3):484-489.

View in: PubMed
Friedlander ML, Russell K, Millis S, Gatalica Z, Bender R, Voss A. Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials. Int J Gynecol Cancer. 2016 May; 26(4):648-54.

View in: PubMed
Mueller JJ, Holzapfel M, Han CH, Santos K, Gunderson C, Moore K, Erickson B, Leath CA, Diaz E, Walsh C, Wethington SL, Dejbakhsh SZ, Barakat RR, Gardner GJ, Hyman DM, Soslow RA, Leitao MM. Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary. Int J Gynecol Cancer. 2016 Jan; 26(1):120-4.

View in: PubMed
Kizer NT, Hatem H, Nugent EK, Zhou G, Moore K, Heller P, Mutch DG, Thaker PH. Chemotherapy Response Rates Among Patients With Endometrial Cancer Who Have Elevated Serum Platelets. Int J Gynecol Cancer. 2015 Jul; 25(6):1015-22.

View in: PubMed

People

Explore

Similar Concepts

Top Journals